Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
Weill Cornell Medicine|NewYork-Presbyterian is a leader in the development of percutaneous transcatheter valve replacement technology (TAVR and TMVR). Our team plays a leading role in the clinical trials assessing the latest percutaneous mitral and aortic valve replacement approaches, giving us more experience than most centers in these emerging new techniques. We have achieved superior outcomes using these innovative approaches, which make valve replacement possible for many patients who otherwise would not tolerate conventional heart surgery.
Patients who come to us receive comprehensive care from a team with exceptional experience in the repair and replacement of heart valves. A patient can meet with cardiologists, surgeons and other healthcare professionals in one day, in one convenient location, to obtain a diagnosis and recommendations for a treatment plan.
Weill Cornell Medicine|NewYork-Presbyterian physicians have participated as investigators in two pivotal clinical trials which established the effectiveness of percutaneous (transcatheter) valve surgery:
Weill Cornell continues to evaluate transcatheter approaches for mitral and aortic valve replacement by participating and enrolling patients in the Everest II, Partner II and Partner III trials.